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Abstract
There is a need to develop a universal vaccine against influenza virus infection to avoid developing new formulations of a
seasonal vaccine each year. Many of the vaccine strategies for a universal vaccine target strain-conserved influenza virus
proteins, such as the matrix, polymerase, and nucleoproteins, rather than the surface hemagglutinin and neuraminidase
proteins. In addition, non-disease-causing viral vectors are a popular choice as a delivery system for the influenza virus
antigens. As a proof-of-concept, we have designed a novel influenza virus immunogen based on the NP backbone
containing human T cell epitopes for M1, NS1, NP, PB1 and PA proteins (referred as NPmix) as well as a construct containing
the conserved regions of influenza virus neuraminidase (N-terminal) and hemagglutinin (C-terminal) (referred as NA-HA).
DNA vectors and vaccinia virus recombinants expressing NPmix (WR-NP) or both NPmix plus NA-HA (WR-flu) in the cytosol
were tested in a heterologous DNA-prime/vaccinia virus-boost vaccine regimen in mice. We observed an increase in the
number of influenza virus-specific IFNc-secreting splenocytes, composed of populations marked by CD4
+ and CD8
+ T cells
producing IFNc or TNFa. Upon challenge with influenza virus, the vaccinated mice exhibited decreased viral load in the
lungs and a delay in mortality. These findings suggest that DNA prime/poxvirus boost with human multi-epitope
recombinant influenza virus proteins is a valid approach for a general T-cell vaccine to protect against influenza virus
infection.
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Introduction
Millions of people worldwide are infected with influenza virus
every year. Although most yearly outbreaks are characterized by
fewer than 40,000 deaths in the United States, highly virulent
strains can evolve that cause worldwide pandemics, resulting in a
dramatically increased incidence of death. While ribavirin and
oseltamvir can be used to combat infection, there has been recent
emergence of strains resistant to these drugs [1], demonstrating the
need for better therapeutics or vaccine strategies against influenza
virus infection.
The major cause of influenza pandemics involves the combi-
nation of the two major glycoproteins on the virion surface [2].
These two glycoproteins, hemagglutinin (HA) and neuraminidase
(NA), contribute to the considerable antigenic variation of
influenza virus because they have 16 and 9 subtypes, respectively.
When a new glycoprotein subtype appears on the virion surface,
the population is immunogenically naı ¨ve to this new strain, raising
the possibility of a pandemic. The worst influenza pandemic to
date occurred in 1918, by the so-called ‘‘Spanish flu,’’ an H1N1
virus, which led to over 40 million deaths worldwide [3]. In 2005,
there were outbreaks of an H5N1 virus in Southeast Asia and
Europe. While this strain caused death in humans, it has been
unable to be transmitted from person to person [4].
Besides increased mortality and morbidity, how else would an
influenza pandemic impact society? Compounded with the fact that
influenza-associated hospitalizations have increased substantially
over the last two decades [5], the economic loss due to another
pandemic would be unimaginable. Based on a model which takes
into account variables such as different types of vaccination
strategies and illness percentages, Thompson et al. proposed that
another pandemic would cause up to 207,000 and 734,000
hospitalizations, and 18 to 42 million outpatient visits in the United
States alone. Based upon these numbers, they estimate that due to
loss of life and medical care, the economic cost of a pandemic to the
United States would be up to $167 billion dollars [6].
The current vaccination strategy against influenza virus consists
of a live-attenuated or killed virus vaccine regimen containing the
three strains of virus (two A subtypes and one B subtype) that are
thought to be most prevalent in the upcoming influenza season.
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bioinformatics analysis of epidemiological data from the previous
season. Since the current vaccine strategy requires changing of the
vaccine formulation every year, there is a push to develop a
universal vaccine [7]. Development of these next generation
influenza vaccines is based on technologies utilizing recombinant
proteins, virus-like particles, viral vectors, and DNA-based
vaccines [8]. Another strategy is prime-boost, using DNA for
priming and virus vectors expressing antigens of interest as a boost
[9]. Attenuated poxvirus vectors, such as MVA and NYVAC, have
been used successfully to induce a greater immune response
towards HIV antigens [10,11,12]. In fact, one of the more
successful HIV vaccine trials in humans to date utilized a poxvirus
vector [13], and there are ongoing phase I/II clinical trials using
the MVA poxvirus vector [12,14,15,16].
Regarding influenza virus, many vaccination strategies have
used the nucleoprotein (NP) as an antigen to induce immune
responses since it is well-conserved across influenza virus subtypes
[17,18,19]. However, in some cases, vaccines developed around
NP have failed to provide protection [20,21]. Recently, MVA
vectors expressing influenza virus antigens have been shown to
provide protection against virus challenge, even in human clinical
trials [22,23,24]. Novel design strategies using viral antigens in
combination with NP may be able to improve immunogenicity to
influenza virus and provide more universal protection.
In this study, we designed recombinant influenza virus antigens
for use in a DNA prime/vaccinia virus boost vaccination strategy,
and studied the ability of these proteins to induce an adaptive
immune response and protective response to heterologous
challenge. One immunogen was designed around influenza virus
NP, which included human epitopes from the M1 (matrix), NS1
(non-structural), PB1 (basic polymerase), and PA (acidic polymer-
ase) viral proteins. The vaccinia virus construct containing NPmix
was referred to as WR-NP. The other immunogen contained
conserved sequences from H5N1 viruses: the N-terminal NA fused
to the C-terminal HA and was combined with the NPmix to
generate the viral vector WR-flu. We also generated plasmid DNA
vectors from pCIneo expressing independently NPmix and HA-
NA. We show that our recombinant vaccinia virus constructs grow
well in cell cultures and produce the recombinant products
(NPmix or both NPmix and NA-HA) in the cytoplasm of infected
cells, similarly as for the DNA vectors. After the DNA prime/
poxvirus boost vaccination protocol in mice we observed increased
IFNc-secreting cells, along with an increased CD4
+ and CD8
+ T
cell response with regard to IFNc
+ and IFNc
+TNFa
+ cells. Upon
challenge with influenza virus, lung viral titers were decreased in
animals vaccinated with the viral vectors expressing recombinant
influenza virus proteins. Taken together, this study demonstrates
how a T cell vaccine based on a DNA prime/poxvirus boost
strategy containing multiple human influenza virus epitopes can
reduce viral load during heterologous challenge and provides a
rational design for the generation of universal influenza vaccines.
Results
Immunogen design and characterization of vaccinia virus
vectors expressing influenza virus antigens
The goal in developing our T cell vaccine against influenza virus
was first to design an immunogen utilizing the conserved regions of
influenza virus proteins as antigens and then to produce a
recombinant vaccinia virus that can be used as a broad-spectrum
vaccine to induce specific immune response to influenza. For this
aim, we generated two types of immunogens. One was based on
the nucleoprotein (NP) as a backbone, which is well-conserved
among H1N1, H2N3, H5N1, H9N2, and H7N7 strains of
influenza virus (Figure S1). Within the NP backbone, we added
conserved human T cell epitopes for other influenza virus proteins,
specifically M1, NS1, PB1, and PA (Figure 1B; NPmix). Briefly, we
were guided by Epstein, et al., which lists the influenza virus gene
products and peptide sequences that are presented by certain
MHC molecules [25]. We narrowed down this list to four M1, one
NS1, one PA, and two PB1 epitopes that were the most conserved
among the virus strains listed in Figure S1. These, in addition to
the NP epitopes, were included in the NPmix recombinant gene
shown in Figure 1B. In choosing the amino acids to swap, we were
careful in selecting regions without significant secondary structure,
and we avoided swapping hydrophilic for hydrophobic regions.
We also did not remove any known NP T cell epitopes. The
second construct involved fusing the conserved regions of
neuraminidase (NA) and hemagglutinin (HA) from H5N1
influenza viruses (Figure 1B and S2; NA-HA). These HA and
NA subtypes are not homologous those in the H3N2, H9N2, or
H7N7 strains listed in Figure S1; however, the NP protein shown
in Fig. S1 is conserved in the H5N1 strains. The NPmix construct
alone or together with the NA-HA construct was inserted in the
TK locus of the Western Reserve strain of vaccina virus
(Figure 1A). We termed the vaccinia virus recombinants
containing NPmix insertion alone ‘‘WR-NP’’ and the insertion
of NPmix and NA-HA ‘‘WR-flu.’’
We also produced plasmid vectors for their use in the priming
stages of the vaccination protocol. The NPmix and NA-HA
immunogens were inserted into the pCIneo mammalian expres-
sion vector, which could efficiently express the proteins upon
transient transfection in cell culture, either transfected alone or in
tandem (Figure 2A). Lower levels of NP and HA were observed
during double transfections since only 5 mg of each vector was
used, as opposed to 10 mg in single transfections. We also verified
that the influenza insert was maintained in the recombinant
viruses, as shown after staining viral plaques from purified viral
stocks for NP and WR protein and observing that the recombinant
viruses produced the same number of plaques expressing NP and
WR proteins (Figure 2B); the H5 HA antibody did not strongly
stain viral plaques. We further tested how the expression of
influenza virus proteins from the recombinant viruses was
dependent on MOI. We observed that the NA-HA and NPmix
protein is strongly expressed by 24 h p.i. during both WR-NP and
WR-flu infection (Figure 2C). Finally, all viruses replicate to
similar levels (Figure 2D). Together, these results indicate that the
recombinant viruses are correctly expressing the influenza virus
proteins and that the expression of these proteins does not alter the
infection profile as compared to wild-type vaccinia virus.
To further characterize the viruses, we examined the subcellular
localization of the influenza virus proteins. The recombinant
proteins were expressed mainly in the cytoplasm of cells during
either WR-NP or WR-flu infection. HA showed a higher degree of
co-localization with viral factories (Figure 3A), as marked by
staining for the 14K vaccina virus protein (A27 gene), as compared
to colocalization of the NP protein with 14K (Figure 3B). NPmix
also exhibits greater distribution throughout the cell.
Immunogenicity of vaccinia virus recombinants during
DNA prime/poxvirus boost vaccination
We next examined the influenza virus-specific immune
responses induced in mice by the WR-NP and WR-flu
recombinant viral constructs. Four BALB/c mice for each group,
WR, WR-NP, or WR-flu, were vaccinated according to the
schedule in Figure 4A and sacrificed to evaluate the adaptive
immune response elicited. Mice were primed with 100 mg DNA by
Vaccinia Virus-Based Influenza Virus Vaccine
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used for the WR group; 100 mg DNA containing the NPmix
vector (pCIneo-NPmix) was used for the WR-NP group; 50 mgo f
NPmix DNA and 50 mg of DNA containing the NAHA vector
(pCIneo-NAHA) was used for the WR-flu group. Two weeks post-
prime, the animals were boosted by intraperitoneal infection of 10
7
PFU of WR, WR-NP, or WR-flu. Eleven days post-boost, the
adaptive immune response was evaluated using a fresh IFNc
ELISPOT assay with splenocyte stimulation using a peptide
corresponding to influenza virus NP (TYQRTRALV) or vaccinia
virus E3 (VGPSNSPTF).
As shown in Figure 4B, animals that were vaccinated with WR-
NP or WR-flu exhibited a significant increase in splenic T cell
responses against the NP peptide. Vaccination with WR-NP lead
to a ,7.6-fold increase in IFNc-secreting cells while vaccination
with WR-flu lead to a ,6.5-fold increase, as compared to
vaccination with WR alone. All vaccination protocols exhibited
similar response levels to the E3 peptide, indicating that all viruses
are replicating similarly in the vaccinated animals. We also
performed experiments to determine the levels of neutralizing
antibodies in the serum of vaccinated mice. However, we did not
observe any significant increase in neutralizing antibodies against
influenza virus nor against NA or HA in mice vaccinated with
WR-NP or WR-flu versus WR alone (data not shown).
Functional profile and polyfunctionality of WR-NP and
WR-flu induced CD4
+ and CD8
+ T cell responses
To determine the phenotypic characteristics of the T cell
populations activated after immunization with the DNA-prime/
poxvirus-boost protocol, we utilized multiparameter intracellular
flow cytometry staining (ICS) analysis to identify influenza virus-
specific T cell responses. Splenocytes from four mice per group
were cultured overnight and then stimulated with the NP-specific
peptide in the presence of brefeldin for 6 h.
Figure 1. Design and characterization of vaccine constructs. (A) Recombinant influenza virus gene constructs (NPmix or NA-HA) were inserted
at the TK locus of the Western Reserve (WR) of vaccinia virus and are driven by the synthetic early/late promoter (pE/L). The cloning vectors (shown)
were introduced into the wild-type WR virus by homologous recombination and iterative plaque purification. (B) Amino acid sequences of NPmix and
NA-HA recombinant influenza virus protein constructs. The backbone for the NPmix construct is influenza virus NP into which was inserted other
influenza virus protein human T cell epitopes. Human T cell epitopes for influenza virus M1, NS1, NP, PB1, and PA proteins are indicated. The NA-HA
construct consists of the conserved regions of H5N1 influenza virus neuraminidase (N-terminal amino acids 108–231) and hemagglutinin (C-terminal
amino acids 347–511).
doi:10.1371/journal.pone.0025938.g001
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WR-flu vaccination protocols induced a greater magnitude of T
cell responses as compared to WR alone. WR-NP induced a ,2.9-
fold increase in T cell response as compared to WR, and WR-flu
induced a ,9.1-fold increase. While T cells secreting cytokines
following WR-NP vaccination were mostly CD8
+, WR-flu induced
both CD4
+ and CD8
+ T cells. However, the CD8
+ T cells
activated following WR-NP infection secreted both IFNc and
TNFa, while the T cells following WR-flu vaccination secreted
mainly IFNc.
The simultaneous measurements of three secreted cytokines
allows for the assessment of the quality of the vaccine-induced
CD4
+ and CD8
+ T cell responses. Upon analyzing concurrent
secretion of IFNc, TNFa, and IL2 by T cells, seven distinct
influenza virus-specific CD4
+ and CD8
+ T cell populations can be
identified. To further characterize the immunogenicity triggered
in each immunized group, we assessed polyfunctional T cell
responses. Regarding CD4
+-secreting T cells (Figure 6A), we
observed only a significant response following WR-flu vaccination,
and this profile was not polyfunctional; CD4
+ T cells secreted only
IFNc. However, WR-flu vaccination increased the overall
magnitude of the CD4
+ T cell response ,19-fold (Figure 6B).
With regard to CD8
+ T cells, we did observe polyfunctionality
following vaccination with WR-NP, but not WR-flu (Figure 6C).
While vaccination with WR-flu elicited significantly higher levels
of CD8
+ T cells secreting IFNc as compared to WR, vaccination
with WR-NP exhibited significant levels of IFNc/TNFa-secreting
CD8
+ T cells. While not statistically significant, WR-NP
vaccination also lead to high levels of triple, IFNc/TNFa/IL2-
secreting, CD8
+ T cells. As compared to vaccination with WR, the
magnitude of the CD8
+ T cell response was ,3.5-fold higher for
WR-NP and ,5.7-fold higher for WR-flu (Figure 6D).
Overall, these results indicated that immunization with WR-NP
induced a polyfunctional influenza virus-specific T cell response,
while immunization with WR-flu was monofunctional with CD4
+
and CD8
+ T cells only producing IFNc. Nevertheless, we show
that WR-NP and WR-flu immunization improved the magnitude
and quality of the anti-influenza virus response compared to WR.
However, even though we observed an adaptive immune response
characterized by polyfunctional T cells, we did not observe a
memory response 53 days post- vaccination with the single NP
peptide used as a test system (data not shown). This apparent lack
of a memory response could be associated with the fact that we did
not observe the production of neutralizing antibodies.
Virus load is reduced in the lungs of mice upon challenge
with influenza virus following vaccination
Upon measuring the adaptive immune response induced by
vaccination with the recombinant DNA and vaccinia virus
constructs, next we determined what effect vaccination had on
challenge with influenza virus. Two weeks following the end of the
vaccination protocol, mice from each vaccination group, along
with 9 mice that had received PBS alone, were infected
intranasally with 106LD50 of the A/WSN/33 (WSN), A/PR/8/
Figure 2. Recombinant viruses synthesize NP and HA proteins and replicate to similar levels. (A) 10 mg of pCIneo (neo) vectors
containing the NPmix (NP) or NA-HA (HA) inserts were transfected into BSC40 cells. For double transfections, 5 mg of each vector was used. 48 h post-
transfection, cells were lysed and levels of influenza virus proteins were determined using antibodies for NP and HA. (B–D) BSC40 cells were infected
with WR, WR-NP, or WR-flu at an MOI of 0.01 (B, D), 0.1, 1, or 10 (C) PFU/cell. (B) At 24 h p.i., cells were fixed and plaques were stained with NP
antibody. (C) At 24 h p.i., the levels of NP and HA in the lysates were determined by immunoblot analysis. (D) At 8 or 24 h p.i., infectious virus present
in the cells was measured in triplicate standard plaque assay on BSC40 cells.
doi:10.1371/journal.pone.0025938.g002
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corresponding to 10
4,1 0
3,o r1 0
5 PFU/mouse, respectively. Each
day following challenge, mice were weighed and sacrificed when
body weight reached at least 75% of their starting weight. While
vaccination with WR-NP or WR-flu did not protect mice from
death or weight loss, mortality was generally delayed by 1–2 days
(Figure 7). However, we did observe a significant decrease in lung
viral titers following vaccination with WR-NP and WR-flu as
compared to WR (Figure 8). WR-NP vaccination decreased lung
viral titers by ,5.2-, ,55-, and ,8.6-fold upon challenge with
WSN, PR8, and CA, respectively. Vaccination with WR-flu lead
to a significant decrease in lung viral titer only upon challenge with
PR8 (,33-fold). We hypothesize that vaccination with WR-NP
resulted in viral titers lower than vaccination with WR-flu because
we observed a higher quality, polyfunctional T cell response
during WR-NP vaccination.
Taken together, our study indicates that recombinant vaccinia
viruses containing human T cell epitopes for influenza virus
proteins embedded in NP or the conserved N-terminal of NA
fused with the conserved C-terminal of HA can elicit specific T cell
immune responses following heterologous vaccination utilizing a
DNA-prime/poxvirus-boost protocol. While we observed signifi-
cant levels of T cells secreting cytokines in a polyfucntional
manner, this was not sufficient to protect mice from mortality;
however, we did observe a decrease in lung viral replication upon
vaccination with the recombinant viruses.
Discussion
The vaccination strategy of heterologous prime-boost vaccina-
tion to elicit specific protective T cell responses has been widely
established ever since its ground-breaking conception almost two
decades ago [26], in which an influenza virus prime followed by
vaccinia virus boost provided protection against Plasmodium
infection in mice. Since this first evidence that vaccinia virus
boost was required for strong activation of specific T cells, many
different techniques have arisen, including the use of different viral
vectors, DNA, and protein, in the presence and absence of
adjuvant. In the present study, we constructed two different
vaccinia virus vectors expressing recombinant influenza virus
Figure 3. Recombinant influenza virus proteins are present in the cytosol of infected cells. BSC40 cells were infected with WR, WR-flu (A),
or WR-NP (B) at an MOI of 1 PFU/cell. At 24 h p.i., cells were fixed with 2% paraformaldehyde, permeabilized, and stained with DAPI or antibodies
recognizing influenza virus HA (A), NP (B), or vaccinia virus 14 K (A27 gene). Bar=25 mm.
doi:10.1371/journal.pone.0025938.g003
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conserved influenza virus proteins. Also utilized in our vaccine
design were the N-terminal of NA and the C-terminal of HA,
which are the well-conserved regions of H5N1 influenza virus
subtypes. These recombinants were part of a DNA-prime/
poxvirus-boost vaccination strategy in which a mammalian
expression vector expressing the same sequences that were inserted
into the vaccinia virus genome was used for the DNA priming
stage. While our vaccination strategy elicited an immune response
marked by CD4
+ T cells expressing IFNc, CD8
+ T cells expressing
IFNc and TNFa, and resulted in decreased viral replication in the
lungs of influenza-virus infected mice, these mice were not
protected against mortality.
There has been some disparity regarding the ability of influenza
virus NP in vaccine constructs to protect mice from mortality. A
recent report describes a human vaccine trial using a vaccinia
virus-based vaccine encoding the NP and M1 proteins against
influenza virus [24]. This vaccine protocol elicited increased IFNc-
secreting CD8
+ T cells in response to NP and M1. On the other
hand, Lawson, et al., observed no protection following vaccination
with vaccinia virus constructs encoding NP, even though they
observed a reduction in lung viral load [20]. Ohba, et al. described
a DNA-based vaccine based on the N-terminal of NP and
observed protection upon challenge with influenza virus [18].
Saha, et al. also observed an improvement in vaccination using NP
when used in conjunction with the VP22 gene of herpes simplex
virus [17]. Finally, Altstein, et al. developed a vaccine using
recombinant NP that included a proteolysis signal which provided
some protection, especially when challenged with low doses of
influenza virus [19]. Therefore, it was our goal to improve upon
vaccine designs based on NP using a strategy in which we included
human T cell epitopes for other influenza virus proteins within the
NP backbone. A strategy based on multiple epitopes was
successfully used to vaccinate against Japanese encephalitis virus
in mice [27], as well as against hepatitis B virus and SIV [28,29].
While we did not specifically test if every influenza virus epitope
was correctly processed and presented, we know that the NP
peptide used for the ELISPOT and ICS experiments was correctly
presented. Following rationale design principles, we expect that
the other epitopes would be presented [30]. However, future
experiments with overlapping peptides for the entire influenza
proteins to fully characterize T cell epitopes, perhaps using a
transgenic humanized MHC class I mouse, should be performed.
In addition to the multi-epitope NPmix recombinant vaccinia
virus, we also constructed a recombinant virus encoding the
conserved regions from HA and NA of H5N1 viruses to examine if
the inclusion of more T cell epitopes would provide cross-clade
protection when challenged with H1N1 viruses.
Although we observed that T cells were able to be stimulated to
produce cytokines with influenza virus antigens, we did not
observe a protection from lethality of the virus. A number of other
Figure 4. Immunogenicity of WR-NP and WR-flu in mice. (A)
Immunization schedule. BALB/c mice were primed with 100 mg of DNA
(either 100 mg pCIneo-NPmix or empty vector, or 50 mg pCIneo-
NPmix+50 mg pCIneo-HANA) intramuscularly (i.m.) at the start of the
vaccination protocol. Two weeks later, the mice were boosted by
intraperitoneal (i.p.) infection with 10
7 PFU of WR, WR-NP, or WR-flu.
Eleven days post-boost, four mice were sacrificed to analyze the
adaptive immune response. The remaining mice were challenged with
influenza virus A/WSN/33, A/PR/8/34, or A/California/07/09. (B) Vaccine-
elicited T cell responses of splenocytes 25 d after the start of the
immunization protocol were measured in triplicate for each immuni-
zation group by fresh IFNc ELISPOT assay following stimulation with
influenza virus NP peptide TYQRTRALV, vaccinia virus E3 peptide
VGPSNSPTF, or RPMI media alone. The results represent the mean
number of IFNc-secreting cells per 10
6 splenocytes from three
biological replicates 6 standard deviations. P values from a two-tailed
t test assuming nonequal variance are indicated (*, P,0.05).
doi:10.1371/journal.pone.0025938.g004
Figure 5. Phenotypic analysis of vaccine-induced CD4
+ and
CD8
+ T cell responses. The same groups of splenocytes as described
in Figure 4 were stimulated with the influenza virus NP-specific peptide
and analyzed using polychromatic flow cytometry. The results represent
the mean number of CD4
+ and CD8
+ T cells secreting IFNc, TNFa, or IL2
in each immunization group using three biological replicates 6
standard error. The background from unstimulated controls was
subtracted in all cases. The pie charts represent the magnitude and
percentage of CD4
+ and CD8
+ T cells secreting cytokines in each
immunization group.
doi:10.1371/journal.pone.0025938.g005
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provide protection from lethality [31,32,33,34,35,36]. It may have
been that our immunization scheme was sub-optimal, or most
importantly, we used the mouse as a test animal. It should be
highlighted that human T cell epitopes were used in the
immunization regimen, and hence, these epitopes in the mouse
might not be properly presented within MHC class I to stimulate
T cells. This is why we had used only a known NP mouse epitope
for stimulation of splenocytes for ELISPOT and ICS experiments.
Also, it may be that the vaccinia virus boost suppressed the
presentation of NP-generated T cell epitopes, as previously
reported [37]. Since we challenged mice with 106LD50, this
may have been too high of a dose to observe the protective effects
of vaccination. While we did observe a decrease in viral replication
in the lungs of mice vaccinated with WR-NP and WR-flu, the
amount of virus in the lungs was still greater than 10
4 PFU/ml,
which is high enough to cause lethality in mice [38]. It is likely that
mouse lung pathology would be similar in all vaccination groups,
and this would have contributed to mortality. Additionally, since
our vaccine construct utilized a muti-epitope design, we may have
observed increased immunogenicity upon stimulating splenocytes
or T cells, if instead of the single NP peptide that we used pools of
peptides spanning the influenza virus NP, M1, NS1, PB1, and PA
proteins, similar to previously described studies [10,11].
Many approaches exist to improve the vaccine design presented
in this study, one of them being the use of adjuvants. Rapamycin
has been shown to have immunostimulatory effects by improving
antigen presentation and aiding in cytokine production from
macrophages and dendritic cells. Furthermore, it is able to
improve on the generation of memory CD8
+ T cells following
vaccination with a poxvirus vector [39,40]. Recent results have
shown that STING plays an important role in the generation of
IFNc-secreting CD8
+ T cells [41]. Upon vaccination with a DNA
vaccine, wild-type mice generated significantly increased amounts
of IFNc as compared to STING
2/2 mice in response to peptide
stimulation. These results suggest that the development of an
adjuvant to stimulate STING during vaccination would augment
the immune response to antigen presentation. In addition to the
use of adjuvants, many other future directions exist for the
improvement of our vaccine design to move closer to a universal
influenza virus vaccine. Our constructs that elicit T cell responses
could be combined with a vaccine specifically design to elicit a
humoral B cell-producing neutralizing antibody response. Sec-
ondly, we would have to test the vaccine for its efficacy in
protection after challenge with other influenza virus subtypes, such
as H5N1, H3N2, H9N2, and H7N7, all of which contain
conserved NP genes. It would also be prudent to challenge with
influenza B subtypes, since seasonal influenza virus vaccines
contain an attenuated B subtype virus. Since challenge with wild-
type H5N1 strain of influenza virus requires high biosafety levels,
we could challenge with a recombinant strain of PR8 that
expresses HA and NA from H5N1 viruses.
In summary, our study describes the design and development of
recombinant DNA and vaccinia virus vaccine constructs for use in
a DNA-prime/poxvirus-boost vaccine protocol as proof-of concept
protocol for a universal vaccine candidate against influenza virus.
Since these experiments were performed with the aim to show
proof-of-principle, we used the replication-competent WR strain
Figure 6. Polyfunctionality of influenza virus-specific CD4
+ and CD8
+ T cells. (A, C) Functional composition of CD4
+ (A) or CD8
+ (C) T cells
responses against influenza virus NP peptide based on the secretion of IFNc, IL-2, or TNFa. All the possible combinations of the responses are shown
on the x-axis, whereas the percentages of the functionally distinct cell populations are shown on the y-axis. Bars correspond to the fraction of
different functionally distinct T-cell populations within total CD4
+ or CD8
+ populations. Responses are grouped and color-coded on the basis of the
number functions. (*, P,10
25; **, P,10
225) (B, D) The pie chart summarizes the data and each slice of the pie correspond to the fraction of CD4
+ T
cells with a given number of functions within the total CD4
+ (B) or CD8
+ (D) T cell populations. The size of the pie chart represents the magnitude of
the specific influenza virus immune response induced.
doi:10.1371/journal.pone.0025938.g006
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non-replicative and safe, attenuated vaccinia virus strains, such as
MVA or NYVAC [12] must be used. Our construct contains
multiple T cell epitopes against influenza virus antigens, which
were aimed to broaden and increase immune responses upon
influenza virus challenge. While our construct elicited an immune
response marked by increased CD4
+ and CD8
+ T cells expressing
IFNc or TNFa, and resulted in decreased viral replication in the
lungs of influenza-virus infected mice, these mice were not
protected against mortality. Taken together, our results suggest
that a human mutli-epitope vaccine design in a DNA prime/
poxvirus boost approach can stimulate the breath and quality of
specific T cell immune responses to influenza virus antigens
leading to reduction in viral load in the lungs. This reduction
might play an important role to limit influenza virus replication in
a natural infection and to develop host immune resistance. The
protocol of immunization described here can be further improved
through the use of a recombinant attenuated vaccinia virus strain,
like MVA, and combination with adjuvants and vectors inducing
neutralizing antibodies to influenza virus proteins. Hence, a
vaccine construct that elicits broad T cell responses and limits virus
replication to some extent, as described here, could be combined
with a second vaccine that elicits a neutralizing antibody response
to further restrict the virus load. Together, such a vaccine strategy
could bring us closer to creating a universal vaccine against
influenza virus infection.
Materials and Methods
Cells, viruses, and infections
BSC40 monkey kidney epithelial cells and Madin-Darby canine
kidney (MDCK) cells (ATCC) were grown as monolayers in
supplemented high glucose Dulbecco’s modified Eagle’s medium
(hgDMEM) supplemented to contain 2 mM L-glutamine, 0.1 mM
nonessential amino acids, Fungizone Amphotencin B (0.5 mg/ml),
penicillin G (100 units/ml), streptomycin sulfate (100 mg/ml) and
10% newborn calf serum (NCS) or fetal calf serum (FCS) (Sigma),
respectively. Wild-type vaccinia virus (strain WR) and recombi-
nant WR viruses expressing influenza virus proteins were grown
and plaque-purified on monkey BSC-40 cells, purified by two 45%
(w/v) sucrose cushions, and titrated on BSC40 cells by plaque
assay.
Near-confluent monolayers of cells were mock-infected or
infected with vaccinia virus diluted in supplemented hgDMEM
Figure 7. Vaccination delays mortality in influenza virus-challenged mice. Two weeks following the end of the vaccination protocol, 5–8
mice from each vaccination group and 9 mice from control PBS-inoculated animals were infected with 106LD50 of the A/WSN/33 (A, B), A/PR/8/34 (C,
D), or A/California/07/09 (E, F) strains of influenza virus. Mice were sacrificed when body weight reached 75% of starting weight.
doi:10.1371/journal.pone.0025938.g007
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adsorption at 37uC, virus and medium was removed. Fresh
supplemented hgDMEM containing 2% NCS was added to the
cells and infections were allowed to proceed at 37uC until the
indicated time post-infection.
Mouse inoculations
At day 1, six- to eight-week old mice BALB/c mice (Harlan)
were anesthetized with isoflurane and injected intramuscularly
with PBS alone or 100 mg of empty pCIneo vector or containing
NPmix, NA-HA, or both (n=19–27). At day 15, mice were
anesthetized and infected intraperitoneally with 10
7 PFU of WR,
WR-NP, or WR-flu. At day 26, four animals were sacrificed for
adaptive immune response analysis. At day 29, the remaining mice
were anesthetized and challenged intranasally with 106LD50 of
the A/WSN/33, A/PR/8/34, or A/California/07/09 strains of
influenza virus (n=5–8 for each group). Animals were weighed
each day for ten days and sacrificed when they lost at least 25% of
their starting body weight. Blood and lung tissue was collected
from each mouse at the time of sacrifice. All experiments were
performed in a specially separated negative-pressure HEPA (high-
efficiency particulate air)-filtered biosafety level 2 laboratory. All
animals were handled in strict accordance with good animal
practice as defined by the relevant national, international, and/or
local animal welfare bodies, and with the Royal Decree (RD
1201/2005). All animal work was approved by the Ethical
Committee of Animal Experimentation (CEEA-CNB) of the
Centro Nacional de Biotecnologı ´a (CNB-CSIC). Permit number:
10015.
Generation and verification of recombinant vaccinia
viruses
Genes for expression of the recombinant influenza virus
proteins, NPmix and NA-HA (Figure 1B) were designed by us
and sent to GeneArtH for synthesis and insertion into the
pBlueScript vector. During the optimization process for the
sequences, the following cis-acting sequence motifs were
avoided: internal TATA-boxes, chi-sites and ribosomal entry
sites; AT-rich or GC-rich sequence stretches; ARE, INS, CRS
sequence elements; repeat sequences and RNA secondary
structures; (cryptic) splice donor and acceptor sites, branch
p o i n t s ;a n dA s c I ,F s e I ,N o t I ,P m l Ia n dS a l Is i t e s .T h ei n f l u e n z a
virus genes were codon optimized and contain either an N-
terminal FLAG tag (NPmix) or a C-terminal His tag (NA-HA).
The genes were individually cloned into pCIneo for mammalian
expression, and also cloned into the TK locus of vaccinia virus
using the transfer vector pCyA. In this vector NPmix was
inserted alone, or in front of NA-HA, both of which were driven
by the vaccinia virus early/late promoter (pE/L). Homologous
recombination in the wild-type vaccinia virus strain WR was
performed as previously described [42]. Recombinant virus
containing NPmix was called ‘‘WR-NP,’’ and virus containing
both NPmix and NA-HA was called ‘‘WR-flu’’. Expression of
the influenza genes was driven by a synthetic early/late virus
promoter (Figure 1A).
Protein analyses and plaque assays
Following vaccinia virus infection or transfection with the
pCIneo expression vectors using Lipofectamine 2000 (Invitrogen)
following the manufacturer’s instructions, cells were lysed at the
indicated times p.i. in disruption buffer (0.5% Triton X-100,
50 mM KCl, 50 mM NaCl, 20 mM Tris-HCl [pH 7.5], 1 mM
EDTA, 10% glycerol, 16 Complete protease inhibitor (Roche),
25 mM b-glycerophosphate, 1 mM Na3VO4). Total protein
content was determined for clarified cell lysates by using the
BCA protein assay kit (Pierce). Lysates were separated by SDS-
PAGE with the same amount of total protein being loaded into
each lane and then transferred onto nitrocellulose membranes.
Immunoblots were blocked for 1 h in PBS containing 0.5%
Tween 20 and 5% nonfat dry milk, washed in PBS containing
0.05% Tween 20, and incubated at 4uC overnight with a mouse
monoclonal actin antibody (MP Biochemicals), a rabbit polyclonal
NP antibody (a kind gift from Adolfo Garcı ´a-Sastre), or a sheep
polyclonal HA antibody (provided by the National Institute for
Biological Standards and Control) in PBS containing 0.5% Tween
20 and 1% nonfat dry milk. Subsequently, membranes were
washed and incubated for 2 h with horseradish peroxidase-
conjugated goat anti-mouse, goat anti-rabbit, or donkey anti-
sheep immunoglobulin G (Sigma), and bound antibodies were
detected with Amersham ECL Western blotting detection reagent
(GE Healthcare).
At the indicated times post-infection, vaccinia virus-infected
cells and cell media supernatant were collected and assayed in
triplicate for viral yield by standard plaque assay on BSC40
cells. For influenza virus-infected mice, diaphragmatic lung
lobes from each animal were weighed, homogenized in PBS, and
samples were then assayed in triplicate for viral yield by stan-
dard plaque assay on MDCK cells. Viral yields were calculated
according to the formula: log yieldt=x=[log10(PFU/ml)t=x]/
[log10(PFU/ml)t=0], where t is time and x is the time post-infection.
For immunostaining of vaccinia virus plaques, infected cells
were fixed 24 h p.i. with 1:1 methanol:acetone, washed in PBS,
then incubated for 2 h with primary antibodies for vaccinia virus
(WR strain) or influenza virus NP diluted in PBS containing 3%
FCS. Cells were then washed and incubated for 1 h with
horseradish peroxidase-conjugated goat anti-rabbit diluted in
PBS containing 3% FCS. The spots were developed in PBS
containing 1 mg/ml of the substrate 3,39-diaminobenzidine
tetrahydrochloride (Sigma) with 0.03% hydrogen peroxide and
0.03% nickel sulfate.
Figure 8. Vaccination reduces the levels of infectious virus in
the lungs of influenza virus-challenged mice. Two weeks
following the end of the vaccination protocol, mice from each
vaccination group were infected with 106LD50 of the A/WSN/33
(WSN), A/PR/8/34 (PR8), or A/California/07/09 (CA) strains of influenza
virus. Mice were sacrificed at 5 d p.i. (except for some mice challenged
with CA that died at 3–4 d p.i), and diaphragmatic lung lobes were
isolated and homogenized. Levels of infectious virus were determined
in triplicate by plaque assay on MDCK cells. The results represent the
mean activity of 5–8 independent samples per group 6 standard
deviation. P values from a two-tailed t test assuming nonequal variance
are indicated (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0025938.g008
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Following influenza virus infection of cells cultured on glass
coverslips, cells were fixed in 2% paraformaldehyde in PBS,
permeabilized in 0.1% Triton X in PBS, washed with 2.5% FCS
and 10 mM glycine in PBS, and then blocked with 10% FCS in
PBS. Cells were then incubated for 2 h with primary antibodies
recognizing influenza virus NP, HA, or vaccinia virus 14 K (A27
gene) diluted in 10% FCS in PBS. Subsequently, cells were washed
and incubated for 1 h with Alexa 488- or 586-conjugated anti-
rabbit immunoglobulin G (IgG) (Invitrogen), or fluorescein
isothiocyanate (FITC)-conjugated donkey anti-sheep IgG (Jackson
Immunoresearch). Cells were washed and incubated for 20 min
with DAPI (49,69-diamidino-2-phenylindole) (Sigma) and mounted
onto glass slides using ProLong Antifade reagent (Invitrogen). Cells
were imaged with the Leica TCS SP5 multispectral confocal
microscope (Leica Microsystems) using photomultipliers for laser
lines 405, 488, and 561 nm. LAS AF v.2.3.6 software was used for
image acquisition.
IFNc ELISPOT assay
The vaccine-specific cellular immune response in mice was
determined using ELISPOT assay measuring the secretion of
IFNc by splenocytes after stimulation with a peptide specific for
influenza virus NP (TYQRTRALV), as previously described
[10,11]. Briefly, eleven days after boosting with vaccinia virus,
mice were sacrificed and splenocytes depleted of red blood cells
were isolated. 10
6 splenocytes were plated in triplicate in 96-well
nitrocellulose-bottomed plates previously coated with 6 mg/ml of
anti-mouse IFNc mAb R4-6A2 (Pharmingen). Cells were
stimulated with the influenza virus-specific peptide (2 mg/ml), a
positive control peptide against the E3 protein of vaccinia virus
(VGPSNSPTF, 5 mg/ml), or without peptide as a negative control.
48 h after stimulation, cells were washed and those secreting IFNc
were developed using a biotin-streptavidin sandwich system and
counted using a stereomicroscope.
Intracellular Cytokine Staining (ICS) assay
Multiparameter flow cytometry was performed as previously
described [10,11]. Briefly, 10
6 splenocytes were stimulated with
the peptides described above in the presence of 1 ml/ml Brefeldin
(BD Bioscience) for 6 hours in a 96-well plate. The cells were then
washed, stained with the LIVE/DEAD Kit (Invitrogen), and Fc
receptors were blocked using CD16/CD32 antibodies (BD
Biosciences). The cells were then stained with the surface-specific
mouse antibodies, CD4-Alexa700, CD3-FITC, and CD8-PerCP
(BD Biosciences). Cells were permeabilized using the BD Cytofix/
Cytoperm Kit and were stained for the intracellular cytokines,
IFNc-APC, IL2-PE and TNFa-PECy7. Sample acquisition was
performed with an LSRII Flow Cytometer and FACSDiva
software (BD Biosciences) and was further analyzed with FlowJo
(Tree Star). All statistical analysis was performed as previously
described [10,11].
Supporting Information
Figure S1 Alignment of nucleoprotein (NP) from various
influenza virus subtypes. The NP protein of five influenza
virus strains of different subtypes (H1N1, H2N3, H5N1, H9N2,
and H7N7, from top to bottom) was aligned. The conserved
region, as indicated by red underline, from amino acids 19–498,
was used as the backbone for the NPmix multi-epitope protein.
(TIF)
Figure S2 Alignment of hemagglutinin (HA) and neur-
aminidase (NA) from different strains of the H5N1
influenza virus subtype. The NA protein (A) or HA protein
(B) from seven or eight different H5N1 viruses were aligned. The
conserved N-terminal of NA (amino acids 107–231) and conserved
C-terminal of HA (amino acids 347–511), as indicated by red
underline, were fused and used for the NA-HA construct along
with NPmix in the WR-flu recombinant virus.
(TIF)
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